Anti-THOC1 Antibody, clone 5N17 ZooMAb^® Rabbit Monoclonal

Quality Control Testing

Evaluated by Western Blotting in lysate from Jurkat cells.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected THOC1 in lysate from Jurkat cells.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected THOC1 in lysates from human brain tissue, mouse brain tissue, and rat brain tissue.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected THOC1 in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound THOC1 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected THOC1 in HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 5N17 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects THOC1. It targets an epitope within 23 amino acids from the N-terminal half.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

THO complex subunit 1 (UniProt: Q96FV9; also known as Nuclear matrix protein p84, p84N5, hTREX84) is encoded by the THOC1 (also known as HPR1) gene (Gene ID: 9984) in human. The gene THOC1 is mapped to human chromosome 18p11.32-p11.31. THOC1 is a component of THO, a RNP (ribonucleoprotein) complex and is also involved in formation of larger RNP complexes like TREX (transcription export). THO participates in transcriptional elongation, transcript 3 end formation and nuclear export. THOC1 interacts with various RNA-binding proteins and is critical for the integrity of mRNA during transport. It has been shown to associate with elongating RNA polymerase II, and UAP56 (spliceosome RNA helicase DDX39B). Structurally, THOC1 is composed of multiple protein domains (including Dock and Death domains) that facilitate interactions with RNA and other proteins like THOC2. An intact death domain is needed for its apoptotic function. THOC1 is ubiquitously expressed with notable levels in tissues such as the brain and liver, and it is regulated during cellular stress responses. Subcellularly, THOC1 is localized primarily in the nucleus but, it shuttles between nucleus and the cytoplasm. Nuclear localization is required for induction of apoptotic cell death. Two isoforms of THOC1 have been described that are produced by alternative splicing. Dysregulation of THOC1 has been implicated in several diseases, including cancer and neurodegenerative disorders, where altered mRNA processing and transport contribute to disease pathology. THOC1 is up-regulated in breast tumors and is correlated with metastatic state of the tumor progression. It is also linked with prostate cancer aggressiveness and on the other hand, THOC1 suppresses cell growth in lung cancer cells. It also interacts with tumor suppressor retinoblastoma protein and is involved in the apoptotic activities. Studies demonstrated that knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma (HCC) and, positions it as a predictive biomarker and therapeutic target in HCC. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Cai, S., et al. (2020). J. Exp. Clin. Cancer. Res. 39; 135).

KLH-conjugated linear peptide corresponding to 23 amino acids from the N-terminal half of human THOC1.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany